Alison Kodjak
-
Certain high-cost drugs are straining state budgets. A new deal approved Wednesday allows Louisiana to spend a fixed amount for unlimited access to a costly cure. Other states may try to follow suit. -
A quirk in the law gives an older opioid addiction treatment "orphan drug" status — and a period of exclusive market access. That may prevent some new therapies from reaching patients for years. -
Lawmakers in the House and Senate are pressing companies to lower prices for insulin which is essential for many people with diabetes. The price is 10 times higher today than it was 20 years ago.
-
A federal judge has struck down a Medicaid work requirement in Arkansas and Kentucky. This is a major blow to the Trump administration's vision for the health insurance program for low-income people.
-
Justice Department files notice that it agrees with a federal judge's ruling that the ACA should be thrown out. The administration had previously said it wanted only parts of the law invalidated.
-
The Trump administration wants to increase transparency in prescription drug pricing. But health economists say the administration's call to tie prices to what other nations pay might work better. -
Scott Gottlieb, head of the Food and Drug Administration, is resigning, effective next month. The reasons for his resignation are not yet clear, but it appears it was not requested by the White House.
-
In a surprise move, the Food and Drug Administration commissioner announced Tuesday he will resign from his position. Dr. Scott Gottlieb is widely viewed as an effective advocate of public health.
-
A new poll by the Kaiser Family Foundation shows that many people struggle to pay for medicines and that a majority of Americans would welcome a range of government interventions to lower prices. -
Democratic Sen. Kamala Harris, who's a candidate for the 2020 presidential election, has endorsed "Medicare for all." But the details of what that means are rather elusive.
